Biologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
|
|
- Constance Jefferson
- 5 years ago
- Views:
Transcription
1 Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
2 Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips, Abbott, Eli Lilly, Galderma, Novartis, Janssen Cilag, Leo Pharma, Sandoz, Mitsibishu, Sandoz Clinical trials for: Basilea, Pfizer, Eli Lily, Amgen, Abbvie, Philips Lighting, Janssen Cilag, Leo Pharma
3 Clinical Manifestations of Plaque Psoriasis
4 Special skin locations:
5 Comorbidities of plaque psoriasis : Psoriatic arthritis occurs in about 30 % of patients with psoriasis Psoriasis has been associated with an increased risk of cardiovascular disease and cardiovascular risk factors 1-6 Psoriasis has also been associated with an increased risk for Crohn s disease, depression and sleep disorder Wu Y, et al. J Drugs Dermatol. 2008;7(4): Mrowietz U, et al. Arch Dermatol Res. 2006;298(7): Gottlieb AB, et al. J Dermatolog Treat. 2008;19(1): Han C, et al. J Rheumatol. 2006;33(11): Ludwig RJ, et al. Br J Dermatol. 2007;156(2): Gisondi P, et al. J Hepatol. 2009;51(4):
6 The Traditional Stepwise Approach Phototherapy Systemic therapy Methotrexate Ciclosporin Acitretin Apremilast Biologic therapy Anti-TNF Anti-IL-12 /23 Anti Il-17 Anti Il -23 OTC products Rx topical agents Options for long-term treatment Arthritis Adapted from Leonardi CL. Available at: Accessed October 2017
7 Biologic Drugs FDA and EMA approved biologic therapies for moderate-tosevere plaque psoriasis: 1. TNF-a antagonists (adalimumab, etanercept, and infliximab), 2. IL-12/23p40 inhibitor (ustekinumab) 3. IL-17A inhibitor (secukinumab, ixekizumab). 4. IL-17 receptor antagonist 5. IL-23p19 inhibitor (guselkumab) (FDA july 2017)
8 Anti TNF adalimumab, etanercept, and infliximab biosimilars
9 Innate Multiple Targets in the Treatment of Psoriasis; Multiple Biologics Available GENOTYPE Triggers KERATINOCYTES ENVIRONMENT IL-17A Macrophages and mast cells Pro-inflammatory cytokines including TNF Unactivated dendritic cell Adaptive Inflammatory Loop IL-17A IL-17F IL-22 IL-21 TNF TNF IFN-g IL-2 Neutrophils IL-23 Innate lymphoid cells Th17 cells Pro-inflammatory signaling Activated dendritic cells Cell differentiation IL-12 Th1 cells Adapted from Nestle F et al. N Engl J Med. 2009;361:
10 Patients (%) Short Term-Efficacy Biologics 100 PASI 75 and PASI 90 Etanercept, Adalimumab und Ustekinumab (week 12) Infliximab (week10 ) Etanercept 1 25 mg Etanercept 1 50 mg Infliximab 2 5 mg/kg Adalimumab 3 40 mg Ustekinumab 4 45 mg Ustekinumab 4 90 mg 1. Papp KA, et al. Br J Dermatol 2005;152: Reich K, et al. Lancet 2005;366: Menter A, et al. J Am Acad Dermatol 2008;58: Papp K, et al. Lancet 2008;371: PASI 75 PASI 90
11 Mean % PASI improvement Week 33 REVEAL Placebo n=102 n=55 n=70 PASI 75 to 100 PASI 50 to <75 <PASI Adalimumab OLE Week
12 IL-12/23p40 inhibitor Ustekinumab
13 Innate Multiple Targets in the Treatment of Psoriasis; Multiple Biologics Available GENOTYPE Triggers KERATINOCYTES ENVIRONMENT IL-17A Macrophages and mast cells Pro-inflammatory cytokines including TNF Unactivated dendritic cell Adaptive Inflammatory Loop IL-17A IL-17F IL-22 IL-21 TNF TNF IFN-g IL-2 Neutrophils IL-23 Innate lymphoid cells Th17 cells Pro-inflammatory signaling Cell differentiation Activated dendritic cells IL-12 Th1 cells Adapted from Nestle F et al. N Engl J Med. 2009;361:
14 Percentage of Patients Achieving PASI 75 new PHOENIX 1 Long-term efficacy through Year 5 UST 45 mg UST 90 mg % 72.2% 72.0% % 62.3% 63.4% (Weeks 40 76) Randomized withdrawal and retreatment Week Week n 45 mg mg *Note: Placebo cross-over patients are included beginning at Week 24 (i.e. 12 weeks after UST treatment). Analyses were not conducted between Weeks 40 and 76 when the majority of the population was withdrawn from treatment per study design. Analyses resumed at Week 76 when about half of the withdrawn patients had reinitiated UST for at least 12 weeks. Patients who reinitiated treatment after Week 76 were reincluded after at least 12 weeks of re-treatment. Kimball A, et al. Poster presented at EADV Congress, Jun , Verona. Poster PO582.
15 Side effects of anti TNF and anti IL12/23 in psoriatic patients Upper respiratory track infections Opportunistic infections ( very rare in data base) Malignancies ( no clear sign in data base) Congestive heart disease
16 Anti IL IL-17A inhibitor (secukinumab, ixekizumab). 2. IL-17 receptor antagonist ( brodalumab )
17 Innate Multiple Targets in the Treatment of Psoriasis; Multiple Biologics Available GENOTYPE Triggers KERATINOCYTES ENVIRONMENT IL-17A Macrophages and mast cells Pro-inflammatory cytokines including TNF Unactivated dendritic cell Adaptive Inflammatory Loop IL-17A IL-17F IL-22 IL-21 TNF TNF IFN-g IL-2 Neutrophils IL-23 Innate lymphoid cells Th17 cells Pro-inflammatory signaling Cell differentiation Activated dendritic cells IL-12 Th1 cells Adapted from Nestle F et al. N Engl J Med. 2009;361:
18 Differences Between Targeting Th17 Cells and IL-17A Th17 cells produce many different cytokines IL-17A is produced by many different cells besides Th17 LTi cell Th17 cell NKT cells NK cells IL-17A ILC3 Mast cell CD=Cluster of Differentiation; LTi=Lymphoid Tissue Inducer; NK=Natural Killer; NKT=Natural Killer T. IL-17A, IL-21, GM-CSF, IL-22, IL-17F, IL-26, CCL20 γδ T-cells CD8 + T-cell Gaffen SL. Nat Rev Immunol. 2009;9: ; Krueger JG, et al. J Allergy Clin Immunol. 2012;130: ; Lin AM, et al. J Immunol. 2011;187: ; Maddur MS, et al. Am J Pathol. 2012;181:8 18; Villanova F, et al. J Invest Dermatol. 2014;134:
19 Patients achieving a PASI 75 response, % Patients achieving a PASI 75 response, % PASI 75 Response fur IL-17 Inhibitors Low Dose Placebo Group High Dose Between 78% to 90% of patients achieved a response ERASURE FIXTURE AMAGINE-1 Secukinumab 1 Phase 3 Brodalumab 2 Phase 3 UNCOVER Ixekizumab 3 Phase 3 Time Point 12 weeks 12 weeks 12 weeks Dose 150 mg, 300 mg 140 mg, 210 mg 160 mg starting dose, 80 mg every 2 or 4 weeks 1. Langley et al. N Engl J Med 2014;371: Amgen and AstraZeneca Phase 3 Study of Brodalumab [News release]. Accessed September 2, Eli Lilly and Company Phase 3 Study of Ixekizumab [News Release]. Accessed September 2, 2014.
20 Secukinumab: A Fully Human IL 17A-selective Monoclonal Antibody Fully human IgG1k-Antibody Created using Medarex-mice Affinity ~200 pm for human IL-17A Low serum clearance rate and long terminal half-life (~27 days) Ig, Immunglobulin; IL, Interleukin Data on File 20
21 CLEAR Trial Thaçi D, Blauvelt A, et al. Am Acad Dermatol Sep;73(3):
22 POOLED ANALYSIS SAEs: No Clinically Meaningful Differences Between Groups Low Incidence of Serious Adverse Events SEC 300 mg (n = 1410) SEC 150 mg (n = 1395) PBO (n = 793) ETAN (n = 323) Any SAE, n (IR) 85 (7.42) 76 (6.80) 15 (7.54) 20 (7.01) Pneumonia 3 (0.25) 3 (0.26) 0 (0.00) 0 (0.00) Angina pectoris 1 (0.08) 2 (0.18) 0 (0.00) 0 (0.00) Cellulitis 1 (0.08) 2 (0.18) 2 (0.99) 1 (0.34) Abscess bacterial 0 (0.00) 3 (0.26) 0 (0.00) 0 (0.00) Appendicitis 2 (0.17) 1 (0.09) 0 (0.00) 0 (0.00) Coronary artery disease 1 (0.08) 1 (0.09) 0 (0.00) 0 (0.00) Hypertensive crisis 2 (0.17) 1 (0.09) 0 (0.00) 0 (0.00) Psoriasis 1 (0.09) 1 (0.09) 4 (1.99) 1 (0.34) Sciatica 2 (0.18) 2 (0.18) 0 (0.00) 0 (0.00) Most frequent SAEs 0.15 per 100 patient years; entire treatment period (52 weeks) Treatment-emergent SAEs are summarized in this table. IR = incidence rate per 100 patient years. For patients with event, exposure time is censored at time of first event. 22
23 POOLED ANALYSIS Candidiasis: Non-serious Superficial Mucocutaneous Infections Entire Treatment Period Exposure Adjusted (52 Weeks) Higher frequency of non-serious Candida infections reported with 300 mg No cases of systemic or invasive infections Majority of infections mild to moderate None serious; all responded to conventional treatment No discontinuations Candida infections Based on all AEs Based on SAEs SEC 300 mg (n = 1410) SEC 150 mg (n = 1395) PBO (n = 793) ETAN (n = 323) 41 (3.55) 21 (1.85) 2 (1.00) 4 (1.37) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) Gaffen et al 2011; Miller and Cho
24 Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease IL-17-A inhibition, IL-17RA inhibition and IL-17 knockout led to induction or exacerbation of colitis in mouse models. Anti-IL-17 medications are associated with IBD exacerbation. Caution should be used in prescribing these medications in patients with diagnosed IBD or personal history suggestive of IBD. J Hohenberger M, et al J Dermatolog Treat ;29:13-18
25 Side effects of anti IL-17 in psoriatic patients Upper respiratory track infections Opportunistic infections ( no signal) Malignancies ( no signal ) Candidiasis Aggravation IBD
26 Anti IL IL-17A inhibitor (secukinumab, ixekizumab). 2. IL-17 receptor antagonist ( brodalumab ) Class effect / Molecule effect
27 Anti-IL-23 Risankizumab Guselkumab Tildrakizumab
28 Innate Multiple Targets in the Treatment of Psoriasis; Multiple Biologics Available GENOTYPE Triggers KERATINOCYTES ENVIRONMENT IL-17A Macrophages and mast cells Pro-inflammatory cytokines including TNF Unactivated dendritic cell Adaptive Inflammatory Loop IL-17A IL-17F IL-22 IL-21 TNF TNF IFN-g IL-2 Neutrophils IL-23 Innate lymphoid cells Th17 cells Pro-inflammatory signaling Cell differentiation Activated dendritic cells IL-12 Th1 cells Adapted from Nestle F et al. N Engl J Med. 2009;361:
29 Molecular Characteristics of Risankizumab Total molecular mass of ~148 kda Two binding sites for IL-23p19 Two framework mutations in Fc region to reduce binding to Fcγ receptor and complement (FcRn binding preserved) In a Phase 1 study, half-life ranged from 20 to 28 days after a single IV administration 1. Singh S et al. mabs 2015;7: Boehringer Ingelheim. Investigator Brochure, version 7, Data on file Krueger JG et al. J Allergy Clin Immunol 2015;136:
30 Patients with PASI 90 (%) Rizankizumab PASI90 Response (NRI) % 81% 73% 78% 49% 47.6% 40% 46.3% 43% 30% 10% Dose* Dose Last dose 4.7% Week Risa, 18 mg Risa, 90 mg Risa, 180 mg Ustekinumab Papp KA, et al. N Engl J Med Apr 20;376(16): *18 mg risankizumab only given once at Week 0. Analysis includes all patients who were randomised and who received at least one dose of assigned therapy during the study with non-responder imputation.
31 Side effects of anti IL-23 Upper respiratory track infections Opportunistic infections ( no signal) Malignancies ( no signal ) Candidiasis ( no signal Aggravation IBD ( no signal )
32 Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction: A Collaborative Analysis Using International Cohorts. Gulliver WP, Young HM, Bachelez H, et al J Cutan Med Surg Jul 8. pii:
33 Value of biologics in psoriasis is a sustainable disease control more than skin deep Highly effective longterm control of skin manifestations of psoriasis Preventing development of comorbidity
The role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationBiologics in Psoriasis: 2018 and Beyond. Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research
Biologics in Psoriasis: 218 and Beyond Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Biologics in Psoriasis FDA approved TNF inhibitors Etanercept Adalimumab
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationUSTEKINUMAB and BRIAKINUMAB
USTEKINUMAB and BRIAKINUMAB Andrew Blauvelt, M.D. Professor, Dept. of Dermatology and Dept. of Molecular Microbiology & Immunology Oregon Health & Science University Chief, Dermatology Service Veteran
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More informationPsoriasis Pearls. Mark Lebwohl, MD
Psoriasis Pearls Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Psoriasis Pearls Pearl #1 Patients who can
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationWhat's Now, What's Next: Individualizing the Treatment of Patients With Moderate to Severe Psoriasis for the Dermatologist Presentation 1
The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants from Celgene
More informationTranslating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment
Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment This symposium took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory
More informationFaculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2015. The content and views presented in this educational activity are those of the
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationWhen researchers discovered in 1979 that the immunosuppressant
The Evolving Landscape of Psoriasis Treatment April W. Armstrong, MD, MPH,* Kenneth B. Gordon, MD, M. Alan Menter, MD, and Jashin J. Wu, MD Abstract The process of discovering new drugs for plaque psoriasis
More informationIL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future
IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future This symposium took place on 13 th September 2018, as part of the 27 th European Academy of Dermatology and Venereology (EADV) Congress
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationADDITIONAL RESOURCES
ADDITIONAL RESOURCES CURRENT MODEL OF PSORIASIS IMMUNOPATHOGENESIS IL-17 A/FIL-22 GM-CSF Stressed keratinocytes TNF-α Myeloid dendritic cell Keratinocytes Activation IL-23 IL-12 T cells IL-1 BIL-6 TNF-α
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant Thaçi, MD, a Andrew Blauvelt, MD, MBA, b Kristian
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 1.1111/jdv.14878 JEADV ORIGINAL ARTICLE Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-tosevere psoriasis through 5 years of treatment (SCULPTURE
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationSource: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California
Source: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California OVERVIEW Steven R. Feldman, MD, PhD, and Alan Menter, MD, as well as principal investigators,
More informationEmerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis These posters were presented at the 5 th World Psoriasis & Psoriatic Arthritis Conference 2018, held from 27 th 30 th June in Stockholm,
More informationEvaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes
Evaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes Faculty William J. Cardarelli, PharmD Director of Pharmacy Revenue and Supply Atrius Health
More informationIxekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι
Ixekizumab Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A Απρίλιοσ 218 ΕΠΕΜΥ Πόρτο Χέλι ΣΑΜΑΣΗ-ΝΙΚΟ ΛΙΟΗ Καθηγ. Ρευματολογίας Ιατρική χολή Παν. Πατρών Ixekizumab Στοιχεία για το mab
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationBiologic Therapy in Psoriasis: Navigating the Options
CLINICAL REVIEW Biologic Therapy in Psoriasis: Navigating the Options Cather McKay, MD; Katherine E. Kondratuk, BS; John P. Miller, BS; Brittany Stumpf, MD; Erin Boh, MD, PhD PRACTICE POINTS Psoriasis
More informationOff-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy Elizabeth A. Brezinski 2, April W. Armstrong 1 * 1 Department of Dermatology, University of
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationSingle Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis
Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationLINKING PATHOPHYSIOLOGY TO CLINICAL OPTIONS IN PSORIASIS: NEW INSIGHTS INTO INTERLEUKIN-23
LINKING PATHOPHYSIOLOGY TO CLINICAL OPTIONS IN PSORIASIS: NEW INSIGHTS INTO INTERLEUKIN-23 This symposium took place on 29 th September 2017, as part of the 47th Annual European Society for Dermatological
More informationixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.
ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd. 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationBackground: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.
ORIGINAL ARTICLES Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results
More informationRisankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis
NIHR Innovation Observatory Evidence Briefing: November 2017 Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis NIHRIO (HSRIC) ID: 9708 NICE ID: 9191 LAY SUMMARY Plaque
More informationIL-17 and IL-23 antagonists
IL-17 and IL-23 antagonists Prof. Jonathan Barker 1 Key T cell subsets and biologic therapies in psoriasis Girolomoni G, et al. JEADV 2017 2 MoA of biologics targeting T cell pathways p35 IL-12 p40 Ustekinumab
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationWhat s New in the Treatment of Psoriasis
What s New in the Treatment of Psoriasis Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is an
More informationFormulary Decisions and the Evolution of Psoriasis Treatment
perspectives Formulary Decisions and the Evolution of Psoriasis Treatment William Malatestinic, PharmD, MBA; 1 David Amato, MD; 1 Steven R. Feldman, MD, PhD 2 affiliations: 1 Eli Lilly and Company, Indianapolis,
More information4/10/18. Faculty. Disclosures. Confronting Psoriatic Disease: Putting New Tools to Work
Confronting Psoriatic Disease: Putting New Tools to Work Faculty Brad P. Glick, DO, MPH, FAOCD Glick Skin Institute Skin and Cancer Associates Program Director Dermatology Residency Larkin Hospital - Palm
More information1 Introduction. Kim A. Papp 1 April W. Armstrong. Wendell Valdecantos 4
Am J Clin Dermatol (216) 17:79 86 DOI 1.17/s4257-15-161-5 ORIGINAL RESEARCH ARTICLE Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis
More informationPharmacy Medical Necessity Guidelines: Stelara (ustekinumab)
Pharmacy Medical Necessity Guidelines: Effective: November 14, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationPASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?
PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough? This symposium took place on 14 th September 2018, as part of the 27 th European Academy of Dermatology
More informationTargeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Background and Scope January 9, 2018 Background Psoriasis is a common
More informationGaps in the Treatment of Psoriasis and PsA for Systemic Therapy
Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add? CLINICAL TRIAL
CLINICAL TRIAL BJD British Journal of Dermatology Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab R.B. Warren,
More informationPsoriasis: Which Drug for Which Patient? Mark Lebwohl, MD
Psoriasis: Which Drug for Which Patient? Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai DRUG PsA
More informationDERMATOLOGY. The Changing Landscape of Psoriasis Treatment ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH The Changing Landscape of Psoriasis Treatment ABSTRACT Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more
More informationAnti-TNF biologic agents Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology
More informationFROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT
FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT This symposium took place on 15 th September 2017 as a part of the 26th European Academy of Dermatology and Venereology
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 10.1111/jdv.13990 JEADV ORIGINAL ARTICLE Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis
More informationA Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
The new england journal of medicine Original Article A Phase 2 Trial of versus Adalimumab for Plaque Psoriasis Kenneth B. Gordon, M.D., Kristina Callis Duffin, M.D., Robert Bissonnette, M.D., Jörg C. Prinz,
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationOverview of the Last Decade Inflammatory Skin Diseases. Mark Lebwohl, MD
Overview of the Last Decade Inflammatory Skin Diseases Mark Lebwohl, MD ProfessorAnd Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? GENERAL DERMATOLOGY
GENERAL DERMATOLOGY BJD British Journal of Dermatology Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective,
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationDo Psoriasis Therapies Increase the Risk of Skin Cancer? Mark Lebwohl, MD
Do Psoriasis Therapies Increase the Risk of Skin Cancer? Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology The Mount Sinai School of Medicine Disclosure Mark Lebwohl
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationPoster presented on Sunday 05 March, 14:50 14:55; 2017 AAD Meeting, Orlando, Florida, USA
Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: an Analysis of a Phase 3 Extension Trial in Psoriasis A Blauvelt 1, K Reich 2, RB Warren 3, B Sigurgeirsson 4, RG Langley 5, C Papavassilis
More informationBJD British Journal of Dermatology. Summary MEDICAL DERMATOLOGY
MEDICAL DERMATOLOGY BJD British Journal of Dermatology Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results
More informationEfficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Drugs R D (2017) 17:29 51 DOI 10.1007/s40268-016-0152-x REVIEW ARTICLE Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical
More informationAccepted Article. Frequency of and predictors for a high clinical response in psoriasis patients on biologic therapy in daily practice
Received Date : 11-Apr-2016 Revised Date : 15-Jul-2016 Accepted Date : 15-Jul-2016 Article type : Original Article Frequency of and predictors for a high clinical response in psoriasis patients on biologic
More informationWhat s New in Medical Dermatologic Therapy
What s New in Medical Dermatologic Therapy Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationPsoriasis: A Cutaneous or Systemic Disease
Psoriasis: A Cutaneous or Systemic Disease Ian D.R. Landells, MD, FRCPC Clinical Chief Dermatology, Eastern Health Clinical Assistant Professor Disciplines of Medicine and Paediatrics Faculty of Medicine
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationEfficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept
Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept Robert Bissonnette, MD, FRCPC, a Chantal Bolduc, MD, FRCPC, a Yves Poulin, MD,
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationRESEARCH. What is already known about this subject. What this study adds
RESEARCH Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database Steven R. Feldman, MD,
More informationAnti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions
Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions Jillian Frieder 1, Dario Kivelevitch 1, Isabel Haugh 1, Ian Watson 2 and Alan Menter 1 Advancements
More informationBioavailability 55% - 77%
Brand Name: Cosentyx Generic Name: secukinumab Manufacturer 1 : Novartis Pharmaceuticals Corporation Drug Class 2,3 : Antipsoriatic Agent, Interleukin-17A Receptor Antagonist Uses: Labeled Uses 1,2,3 :
More informationICER Public Meeting: Evaluating Emerging Therapies for Psoriasis and Endometriosis
ICER Public Meeting: Evaluating Emerging Therapies for Psoriasis and Endometriosis July 12, 2018 WIFI Network: Student Password: [Open network] Targeted Immunomodulators for Plaque Psoriasis: Effectiveness
More informationPhase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
The new england journal of medicine Original Article Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis K.B. Gordon, A. Blauvelt, K.A. Papp, R.G. Langley, T. Luger, M. Ohtsuki, K. Reich,
More informationPharmacy Accreditation
EASING THE PATIENT BURDEN OF PSORIASIS AND PSORIATIC ARTHRITIS: THE ROLE OF THE SPECIALTY PHARMACIST Claire Lee, PharmD, CSP, CPHQ Clinical Quality Improvement Supervisor Diplomat Flint, Michigan Pharmacy
More informationAbstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
More informationHealth Related Quality of Life: The Impact of Psoriasis When Designing Tailored Treatment Plans
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of October 2015. The content and views presented in this educational activity are those of
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More informationDetails of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet
June 10, 2015 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Refer to: Immediately Tim Coulom; tim.coulom@lilly.com; 317-771-2241
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationPharmacy Medical Necessity Guidelines: Stelara (ustekinumab)
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Type of Review Care Prior Authorization Required Management Not Covered Type of Review Clinical Review SQ: RX/ Pharmacy (RX) or Medical
More informationPsoriasis: From Gene to Clinic
Psoriasis: From Gene to Clinic This symposium took place on Thursday 30 th November 2017, as part of the 8th International Congress of Psoriasis: From Gene to Clinic (G2C) in London, UK Chair People: Richard
More informationUstekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese
Hong Kong J. Dermatol. Venereol. (2011) 19, 59-64 Original Article Ustekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese Ustekinumab SKF Loo, KH Lau, KM Ho Introduction:
More informationWhat s already known about this topic? What does this study add?
REVIEW ARTICLE BJD British Journal of Dermatology Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management* D.M. Saunte,
More informationThe Changing Landscape of Psoriasis: New Horizons for Oral Therapies
The Changing Landscape of Psoriasis: New Horizons for Oral Therapies This symposium took place on 14 th September 2017, as part of the 26th European Academy of Dermatology and Venerology (EADV) Congress
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationPsoriasis Patients with: Integrating New Psoriasis Therapies Into Your Practice
Integrating New Psoriasis Therapies Into Your Practice Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology The Mount Sinai School of Medicine Psoriasis Patients with: Psoriatic
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More information